Agenix readies IND application for ThromboView

Australian pharmaceutical developer Agenix is preparing to submit an investigational new drug (IND) application for its ThromboView radiopharmaceutical to the Food and Drug Administration in the second quarter.

Phase II clinical trials will follow soon after for blood clot imaging agent ThromboView, according to the Brisbane-based firm.

By staff writers
February 12, 2004

Copyright © 2004

Page 1 of 436
Next Page